The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Sp1288
OVERVIEW OF CHRONIC IDIOPATHIC CONSTIPATION: FOCUS ON TREATMENT AND NEW TECHNOLOGY
Date
May 8, 2023
Society: DDW
Chronic constipation affects 11-12% of the world's population. Many food and pharma treatments exist, but choice and timing of therapy can be confusing. Join us to learn more about appropriate use of these treatments and a novel vibrating capsule technology that may improve constipation symptoms via modulation of circadian rhythms.
Sponsored by Vibrant Gastro
RATIONALE: RNA sequencing studies have previously identified impaired barrier function and the subsequent proinflammatory response as critical to the pathogenies of EoE. However, the investigation into disease initiation is often limited by the inability to capture the disease early…
BACKGROUND: Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treatment in advanced liver disease associated with metabolic dysfunction-associated steatohepatitis (MASH), the most severe form of metabolic dysfunction-associated steatotic…
Please join us for an engaging discussion led by Dr. Darren Brenner as he shares important clinical considerations in managing patients with IBS-C. The presentation will include interactive patient case studies, along with efficacy and safety data from two phase three clinical trials…
BACKGROUND: Our previous research has showed that increased sympathetic nervous activity and decreased cannabinoid receptor 1 (CB1) were associated with increased energy expenditure and weight loss following Roux-en-Y gastric bypass (RYGB) in mice…